Preclinical work reported that blocking the astrocytic NF-κB pathway enables amyloid-beta clearance through upregulation of peptidase KLK7. The study describes cell culture evidence alongside Alzheimer's disease mouse model results, tying inflammatory transcriptional repression to a mechanistic route for improved amyloid removal. The work specifically frames NF-κB as a brake on KLK7 expression, where lifting that repression increases amyloid-beta clearance. The findings also imply that inflammatory signaling in glial cells can be linked directly to amyloid-processing capacity rather than only serving as a correlate of neurodegeneration. If validated across additional models and translation-ready biomarkers, the NF-κB–KLK7 axis could become a candidate pathway for combinatorial strategies that couple anti-inflammatory modulation with amyloid-targeted effects.